Provepharm Life Solutions is an independent biopharmaceutical company. Since its inception in 1998, Provepharm Life Solutions has been leveraging its expertise in fine chemistry for the revitalization of known molecules. The group has developed a methylene blue product, which complies with the European and US pharmacopoeia and is marketed as Proveblue® / Provayblue™. It is the only injectable methylene blue product approved by the US Food & Drug Administration (FDA) and has received the orphan drug designation for the treatment of methemoglobinemia in the US.

Provepharm Life Solutions’ strategy is focused on developing Proveblue® / Provayblue™ for new indications, applying its expertise for the revitalisation of other molecules and strengthening its international business.

www.provepharm.fr

INVESTMENT DATE
2018

SECTOR
Biopharma

TRANSACTION TYPE
Buy-Out

GROWTH THEME
Internationalization / Innovation

LOCATION
France